Laboratory and clinical studies of loracarbef

Yuei Irabu, Jun Inadome, Hiroshi Fukuhara, Hiroaki Nakamura, Hiroshi Kaneshima, Katsuyoshi Shimoji, Keizou Kitsukawa, Yoshiteru Shigeno, Atsushi Saito, Kyouko Furugen, Isamu Nakasone, Shinko Taira, Nobutika Kusano, Seitetsu Hokama, Tyoutetsu Hokama

Research output: Contribution to journalArticle

Abstract

We performed bacteriological and clinical evaluations of loracarbef (LCBF), a new oral carbacephem, in respiratory tract infections, with the following results. 1) Antimicrobial activity: The minimum inhibitory concentrations (MICs) of LCBF were measured in 302 clinically isolated strains, and compared with those of cefaclor, cefotiam, cefixime, cefteram and amoxicillin, using the MIC-2000 system. LCBF had wide antimicrobial activity against clinically isolated strains except methicillin-resistant Staphylococcus aureus, Enterococcus faecalis, Enterobacter cloacae, Serratia marcescens, Acinetobacter calcoaceticus and Pseudomonas aeruginosa. 2) Clinical efficacy: LCBF, 200 mg X 3 (600 mg/day), was administered to 4 patients with chronic bronchitis, 5 with acute bronchitis, one with acute pharyngitis, 2 with acute tonsillitis and one with acute pneumonia. Clinical response was excellent in one patient, good in 9, fair in 2, and poor in one. Clinical efficacy was 77%. Three of 4 strains of Haemophilus influenzae were eradicated. One strain of Streptococcus pneumoniae and methicillin-susceptible S. aureus were eradicated. Two strains of Klebsiella pneumoniae and one strain of Moraxella catarrhalis were isolated as superinfections. One strain of P. aeruginosa was isolated as a causative organism, but was not eradicated. Side effects were not observed, but mildly abnormal laboratory findings were noted in one patient.

Original languageEnglish
Pages (from-to)260-266
Number of pages7
JournalCHEMOTHERAPY
Volume41
DOIs
Publication statusPublished - Jan 1 1993

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Fingerprint Dive into the research topics of 'Laboratory and clinical studies of loracarbef'. Together they form a unique fingerprint.

  • Cite this

    Irabu, Y., Inadome, J., Fukuhara, H., Nakamura, H., Kaneshima, H., Shimoji, K., Kitsukawa, K., Shigeno, Y., Saito, A., Furugen, K., Nakasone, I., Taira, S., Kusano, N., Hokama, S., & Hokama, T. (1993). Laboratory and clinical studies of loracarbef. CHEMOTHERAPY, 41, 260-266. https://doi.org/10.11250/chemotherapy1953.41.Supplement3_260